The class action complaint alleges that Zoetis executives misled shareholders regarding the company's competitive standing and product safety. Specifically, the lawsuit claims the company failed to disclose that demand for Librela, a canine pain medication, plummeted after veterinarians grew concerned over FDA warnings about neurological complications in dogs. Furthermore, the filing asserts that Zoetis lost significant market share for its Simparica Trio product to cheaper alternatives, while its dermatology mainstays, Apoquel and Cytopoint, faced mounting pressure from new market entrants.

Because of these undisclosed setbacks, the suit argues that the company’s public statements concerning its business operations lacked a reasonable basis. Investors who held ZTS stock during the specified period may contact the firm to review their legal rights or participate in the action. Participation does not require immediate action, as individual investors may choose their own counsel or remain absent members of the class.